ALICIA (Acalabrutinib in CLL therapy)

Trial Identifier: D8220R00021
Sponsor: AstraZeneca
Start Date: February 2021
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: CLL (Chronic Lymphocytic Leukemia)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Russia, Bashkortostan Republic Ufa, Bashkortostan Republic, Russia, 450054
Russia, Kaliningrad region Kaliningrad, Kaliningrad region, Russia
Russia, Khabarovsk region Khabarovsk, Khabarovsk region, Russia, 680009
Russia, Komi Republic Syktyvkar, Komi Republic, Russia
Russia, Krasnoyarsk region Krasnoyarsk, Krasnoyarsk region, Russia, 660022
Russia, Leningrad region Saint Petersburg, Leningrad region, Russia, 198205
Russia, Moscow region Moscow, Moscow region, Russia, 125284
Russia, Moscow region Moscow, Moscow region, Russia, 129110
Russia, Nizhny Novgorod region Nizhny Novgorod, Nizhny Novgorod region, Russia
Russia, Novosibirsk region Novosibirsk, Novosibirsk region, Russia, 630091
Russia, Sakha Republic Yakutsk, Sakha Republic, Russia, 677008
Russia, Saratov region Saratov, Saratov region, Russia, 410028